|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||434.76 - 434.76|
|52-week range||325.00 - 473.65|
|Beta (5Y monthly)||0.28|
|PE ratio (TTM)||24.48|
|Forward dividend & yield||9.78 (2.25%)|
|Ex-dividend date||18 Mar 2021|
|1y target est||N/A|
Drug/biotech and medical device companies are likely to remain in the spotlight in 2022. Among the large drugmakers Roche (RHHBY), Pfizer (PFE), AbbVie (ABBV), and Merck (MRK) are worth retaining in your portfolio.
Sarah London, Vice Chairman of Centene, joins Yahoo Finance Live to talk about Centene's health care initiatives, CMS changes, and how they are handling COVID-19 hospitalizations.
Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.